evipedia.ai
← Back

Pinealon for Health & Longevity

Created on 10/26/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Pinealon, a three-amino-acid peptide developed in Russia, is used to protect the aging brain and for longer dreaming sleep. Evidence is mainly laboratory and animal work; small human reports lacked placebo comparison, and sleep claims rest on personal accounts alone. Safety data are incomplete: one small study noted fewer blood-forming stem cells, and injectable research-chemical products have uncertain identity and purity. It remains experimental, researched almost only by its developers. (Full Review)

Protocol

Oral capsule approach (Russian bioregulator practice)
100 µg twice daily
Two-week course, as studied in locomotive crew workers
Time of day
Morning and evening
This spacing is common practice; sleep-focused users take it in the evening
Injectable research-peptide approach (US peptide clinics)
No published human dose
No trial, label or named practitioner has published one
Time to effect
Resilience to occupational stress
2 weeks
Reassessed after the cited two-week oral course; onset not measured systematically
Sleep effects
Within days
Reported anecdotally

Benefits

Contraindications
  • Pregnancy and breastfeeding
  • Active or recent cancer
  • Bone-marrow failure or cytopenias
  • Children and adolescents
    •
Key Interactions
Theoretical (inferred from mechanism)
  • Myelosuppressive drugs (methotrexate, chemotherapy)
  • Serotonergic antidepressants (SSRIs, MAOIs)
  • PEPT1-transported drugs (valacyclovir, ACE inhibitors)
  • Sleep medications and OTC sleep aids (zolpidem, melatonin)
  • Other peptide bioregulators (epitalon, Cortexin)
  • Sleep-promoting supplements (glycine, magnesium)
  • Intermittent hypoxia or altitude training
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Suppressed blood-forming stem cells
    •
  • Speculative: Pro-oxidant shift; unknown long-term effects on cell proliferation; contamination and injection reactions from research-grade products; adverse behavioral changes in animals
    •

Monitoring

Marker Target Why
White blood cells with differential 3.4–9.6 ×10⁹/L Safety check: blood-cell suppression
Hemoglobin Men 13.2–16.6 g/dL; women 11.6–15.0 g/dL Safety check: falling values
Platelets Men 135–317 ×10⁹/L; women 157–371 ×10⁹/L Safety check: falling values
ALT 7–55 U/L Safety check: liver injury
Serum creatinine Men 0.74–1.35 mg/dL; women 0.59–1.04 mg/dL Safety check: kidney injury

Cadence: Baseline before a first course; blood count at the end of each two-week course, then every 6 months during repeated courses; ALT and creatinine every 6–12 months

Qualitative Assessment

  • Sleep quality: perceived sleep depth and wearable-estimated REM duration against the two-week baseline
  • Cognitive clarity: memory, focus and word-finding in daily tasks, with repeated cognitive test scores
  • Mental fatigue and stress tolerance: energy across demanding workdays and recovery after stress
  • Injection-site status: redness, swelling or pain for users of injectable products
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.